We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia (SCHIZO-CV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05174533
Recruitment Status : Recruiting
First Posted : December 30, 2021
Last Update Posted : February 1, 2022
Sponsor:
Information provided by (Responsible Party):
Université de Reims Champagne-Ardenne

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Schizophrenia is a psychiatric disorder, affecting 600,000 patients in France. Patients with schizophrenia have life expectancy decrease from 10 to 20 years because of cardiovascular death. Cardiovascular risk factors are numerous: inadequate diet, smoking, alcohol consumption, diabetes, obesity. Primary prevention of cardiovascular risk in patients suffering from schizophrenia is difficult because of understaff in general practitioners and psychiatrists.

Condition or disease Intervention/treatment
Schizophrenia Other: Data collection

Detailed Description:
The aim of the study is to describe prevalence of cardiovascular disorders in patients aged 40 and more with schizophrenia.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia
Actual Study Start Date : January 12, 2022
Estimated Primary Completion Date : May 12, 2022
Estimated Study Completion Date : July 12, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
with schizophrenia
"with schizophrenia" group : patients aged 40 and more with schizophrenia
 Other: Data collection
electrocardiogram


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. QRS morphology [ Time Frame: Day 0 ]
    variation of QRS waves according a standard 12-lead ECG


Secondary Outcome Measures :
  1. cardiac rhythm [ Time Frame: Day 0 ]
    cardiac rhythm disorder according a standard 12-lead ECG


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients aged of 40 and more with schizophrenia
Criteria

Inclusion Criteria:

  • male or female
  • aged of 40 and more
  • with schizophrenia
  • agreeing to participate in the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05174533


Contacts
Layout table for location contacts
Contact: CURRS Université de Reims Champagne-Ardenne 0326918822 ext +33 currs@univ-reims.fr
Contact: Coralie BARBE, MD 0326918822 ext +33 currs@univ-reims.fr

Locations
Layout table for location information
France
Epsmd de l'Aisne Recruiting
Prémontré, Grand-Est, France, 02320
Sponsors and Collaborators
Université de Reims Champagne-Ardenne
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Université de Reims Champagne-Ardenne
ClinicalTrials.gov Identifier: NCT05174533    
Other Study ID Numbers: 2021-011-SCHIZO-CV
First Posted: December 30, 2021    Key Record Dates
Last Update Posted: February 1, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Université de Reims Champagne-Ardenne:
schizophrenia
cardiovascular disorders
prevalence
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders